AIMS: The histological modification produced by neoadjuvant chemoradiation on primary rectal cancer has been investigated by many authors, and a prognostic value of tumor regression grade (TRG) has been identified. Tumor regression grade on metastatic mesorectal lymphnodes has been never evaluated. The purpose of this study is to analyse the TRG on mesorectal lymphnodes (lymphnode regression grade, LRG) after preoperative chemoradiation in rectal cancer patients and to determine the correlation with TRG of primary tumor. METHODS: Surgical specimens from 35 patients who underwent chemoradiation were included. LRG on mesorectal lymphnodes was assessed by immunohistochemistry. Response to treatment was evaluated by a 5-point LRG based on the ratio of residual tumor to fibrosis. RESULTS: Complete pathologic response (LRG 1) was observed in 18 patients (51%). In 4 patients (11%) no regression was observed (LRG 5). In 4 cases only reactive lymphnodes were found. LRG on lymphnodes significantly correlated with TRG on primary tumor (p<0.05). CONCLUSIONS: Neoadjuvant chemoradiation determines a tumor regression on mesorectal lymphnodes as on primary tumor; further studies are needed to evaluate the prognostic value of LRG.
AIMS: The histological modification produced by neoadjuvant chemoradiation on primary rectal cancer has been investigated by many authors, and a prognostic value of tumor regression grade (TRG) has been identified. Tumor regression grade on metastatic mesorectal lymphnodes has been never evaluated. The purpose of this study is to analyse the TRG on mesorectal lymphnodes (lymphnode regression grade, LRG) after preoperative chemoradiation in rectal cancerpatients and to determine the correlation with TRG of primary tumor. METHODS: Surgical specimens from 35 patients who underwent chemoradiation were included. LRG on mesorectal lymphnodes was assessed by immunohistochemistry. Response to treatment was evaluated by a 5-point LRG based on the ratio of residual tumor to fibrosis. RESULTS: Complete pathologic response (LRG 1) was observed in 18 patients (51%). In 4 patients (11%) no regression was observed (LRG 5). In 4 cases only reactive lymphnodes were found. LRG on lymphnodes significantly correlated with TRG on primary tumor (p<0.05). CONCLUSIONS: Neoadjuvant chemoradiation determines a tumor regression on mesorectal lymphnodes as on primary tumor; further studies are needed to evaluate the prognostic value of LRG.
Authors: Christina L Roland; Anthony D Yang; Matthew H G Katz; Deyali Chatterjee; Huamin Wang; Heather Lin; Jean N Vauthey; Peter W Pisters; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Jeffrey E Lee; Jason B Fleming Journal: Ann Surg Oncol Date: 2014-10-29 Impact factor: 5.344
Authors: Guus M J Bökkerink; Eelco J R de Graaf; Cornelis J A Punt; Iris D Nagtegaal; Heidi Rütten; Joost J M E Nuyttens; Esther van Meerten; Pascal G Doornebosch; Pieter J Tanis; Eric J Derksen; Roy S Dwarkasing; Corrie A M Marijnen; Annemieke Cats; Rob A E M Tollenaar; Ignace H J T de Hingh; Harm J T Rutten; George P van der Schelling; Albert J Ten Tije; Jeroen W A Leijtens; Guido Lammering; Geerard L Beets; Theo J Aufenacker; Apollo Pronk; Eric R Manusama; Christiaan Hoff; Andreas J A Bremers; Cornelelis Verhoef; Johannes H W de Wilt Journal: BMC Surg Date: 2011-12-15 Impact factor: 2.102
Authors: Claudio Belluco; Antonino De Paoli; Vincenzo Canzonieri; Roberto Sigon; Mara Fornasarig; Angela Buonadonna; Giovanni Boz; Roberto Innocente; Tiziana Perin; Marta Cossaro; Jerry Polesel; Francesco De Marchi Journal: Ann Surg Oncol Date: 2011-06-21 Impact factor: 5.344
Authors: Christiane Jakob; Daniela E Aust; Birgit Liebscher; Gustavo B Baretton; Kaustubh Datta; Michael H Muders Journal: PLoS One Date: 2011-11-07 Impact factor: 3.240
Authors: Sung Min Jung; Chang Sik Yu; In Ja Park; Tae Won Kim; Jong Hoon Kim; Yong Sik Yoon; Seok-Byung Lim; Jin Cheon Kim Journal: Medicine (Baltimore) Date: 2016-05 Impact factor: 1.889
Authors: Jun Li; Jiatian Yuan; Hao Liu; Jie Yin; Sai Liu; Feng Du; Junjie Hu; Ci Li; Xiangke Niu; Bo Lv; Shasha Xing Journal: Oncotarget Date: 2016-03-29